騰訊(00700.HK)與博世中國達成戰略合作
據內地傳媒報道,於騰訊(00700.HK)與博世中國宣佈達成戰略合作,雙方將在物聯網、人工智能等領域開展深入合作,共同推進移動出行的數字化轉型進程。報道指騰訊和博世中國將圍繞移動出行領域的數字化業務展開多項合作,包括:共同為整車廠打造領先的智能座艙解決方案;共同發掘數據價值,為汽車行業和消費者提供智能車載服務、內容服務、自動駕駛等創新增值服務;共同探索創新技術和業務模式,促進雙方和行業的發展和升級。
另雙方將加強在未來智能出行上的協同創新,為博世加速數字化轉型升級和騰訊推進產業化解決方案創新奠定堅實的基礎。(el/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.